Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2018

Open Access 01-12-2018 | Review

Immune cell subset differentiation and tissue inflammation

Authors: Pu Fang, Xinyuan Li, Jin Dai, Lauren Cole, Javier Andres Camacho, Yuling Zhang, Yong Ji, Jingfeng Wang, Xiao-Feng Yang, Hong Wang

Published in: Journal of Hematology & Oncology | Issue 1/2018

Login to get access

Abstract

Immune cells were traditionally considered as major pro-inflammatory contributors. Recent advances in molecular immunology prove that immune cell lineages are composed of different subsets capable of a vast array of specialized functions. These immune cell subsets share distinct duties in regulating innate and adaptive immune functions and contribute to both immune activation and immune suppression responses in peripheral tissue. Here, we summarized current understanding of the different subsets of major immune cells, including T cells, B cells, dendritic cells, monocytes, and macrophages. We highlighted molecular characterization, frequency, and tissue distribution of these immune cell subsets in human and mice. In addition, we described specific cytokine production, molecular signaling, biological functions, and tissue population changes of these immune cell subsets in both cardiovascular diseases and cancers. Finally, we presented a working model of the differentiation of inflammatory mononuclear cells, their interaction with endothelial cells, and their contribution to tissue inflammation. In summary, this review offers an updated and comprehensive guideline for immune cell development and subset differentiation, including subset characterization, signaling, modulation, and disease associations. We propose that immune cell subset differentiation and its complex interaction within the internal biological milieu compose a “pathophysiological network,” an interactive cross-talking complex, which plays a critical role in the development of inflammatory diseases and cancers.
Literature
1.
Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145–73.PubMedCrossRef
2.
Hayakawa K, et al. The “Ly-1 B” cell subpopulation in normal immunodefective, and autoimmune mice. J Exp Med. 1983;157(1):202–18.PubMedCrossRef
3.
Vremec D, et al. The surface phenotype of dendritic cells purified from mouse thymus and spleen: investigation of the CD8 expression by a subpopulation of dendritic cells. J Exp Med. 1992;176(1):47–58.PubMedCrossRef
4.
Passlick B, Flieger D, Ziegler-Heitbrock HW. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood. 1989;74(7):2527–34.PubMed
5.
Stein M, et al. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med. 1992;176(1):287–92.PubMedCrossRef
6.
7.
Yang WY, et al. Pathological conditions re-shape physiological Tregs into pathological Tregs. Burns Trauma. 2015;3(1)
8.
Yanez, A., et al., Granulocyte-monocyte progenitors and monocyte-dendritic cell progenitors independently produce functionally distinct monocytes. Immunity, 2017. 47(5): p. 890–902 e4.
9.
10.
11.
Hettinger J, et al. Origin of monocytes and macrophages in a committed progenitor. Nat Immunol. 2013;14(8):821–30.PubMedCrossRef
12.
Germain RN. T-cell development and the CD4-CD8 lineage decision. Nat Rev Immunol. 2002;2(5):309–22.PubMedCrossRef
13.
Hogquist KA, Baldwin TA, Jameson SC. Central tolerance: learning self-control in the thymus. Nat Rev Immunol. 2005;5(10):772–82.PubMedCrossRef
14.
15.
Sakaguchi S, Wing K, Miyara M. Regulatory T cells—a brief history and perspective. Eur J Immunol. 2007;37(Suppl 1):S116–23.PubMedCrossRef
16.
Harrington LE, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6(11):1123–32.PubMedCrossRef
17.
Dai J, et al. Metabolism-associated danger signal-induced immune response and reverse immune checkpoint-activated CD40(+) monocyte differentiation. J Hematol Oncol. 2017;10(1):141.PubMedPubMedCentralCrossRef
18.
Hsieh CS, et al. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science. 1993;260(5107):547–9.PubMedCrossRef
19.
20.
Littman DR, Rudensky AY. Th17 and regulatory T cells in mediating and restraining inflammation. Cell. 2010;140(6):845–58.PubMedCrossRef
21.
Tran DQ, Ramsey H, Shevach EM. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood. 2007;110(8):2983–90.PubMedPubMedCentralCrossRef
22.
23.
24.
Galy A, et al. Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset. Immunity. 1995;3(4):459–73.PubMedCrossRef
25.
Kondo M, Weissman IL, Akashi K. Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell. 1997;91(5):661–72.PubMedCrossRef
26.
27.
28.
Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. II. Functional properties in vitro. J Exp Med. 1974;139(2):380–97.PubMedPubMedCentralCrossRef
29.
Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med. 1973;137(5):1142–62.PubMedPubMedCentralCrossRef
30.
31.
Helft J, et al. Origin and functional heterogeneity of non-lymphoid tissue dendritic cells in mice. Immunol Rev. 2010;234(1):55–75.PubMedCrossRef
32.
Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol. 2004;5(12):1219–26.PubMedCrossRef
33.
34.
Murphy TL, et al. Transcriptional control of dendritic cell development. Annu Rev Immunol. 2016;34:93–119.PubMedCrossRef
35.
Cisse B, et al. Transcription factor E2-2 is an essential and specific regulator of plasmacytoid dendritic cell development. Cell. 2008;135(1):37–48.PubMedPubMedCentralCrossRef
36.
Bender A, et al. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods. 1996;196(2):121–35.PubMedCrossRef
37.
38.
Yang J, et al. Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases. Biomark Res. 2014;2(1):1.PubMedPubMedCentralCrossRef
39.
Yang J, et al. Chronic kidney disease induces inflammatory CD40+ monocyte differentiation via homocysteine elevation and DNA hypomethylation. Circ Res. 2016;119(11):1226–41.PubMedPubMedCentralCrossRef
40.
Palframan RT, et al. Inflammatory chemokine transport and presentation in HEV: a remote control mechanism for monocyte recruitment to lymph nodes in inflamed tissues. J Exp Med. 2001;194(9):1361–73.PubMedPubMedCentralCrossRef
41.
Leon B, et al. Dendritic cell differentiation potential of mouse monocytes: monocytes represent immediate precursors of CD8- and CD8+ splenic dendritic cells. Blood. 2004;103(7):2668–76.PubMedCrossRef
42.
Jung S, et al. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol. 2000;20(11):4106–14.PubMedPubMedCentralCrossRef
43.
Fleming TJ, Fleming ML, Malek TR. Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family. J Immunol. 1993;151(5):2399–408.PubMed
44.
Nahrendorf M, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med. 2007;204(12):3037–47.PubMedPubMedCentralCrossRef
45.
Van Furth R, Diesselhoff-den Dulk MC, Mattie H. Quantitative study on the production and kinetics of mononuclear phagocytes during an acute inflammatory reaction. J Exp Med. 1973;138(6):1314–30.PubMedPubMedCentralCrossRef
46.
Nathan CF, et al. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med. 1983;158(3):670–89.PubMedCrossRef
47.
48.
Rosenfeld ME. Converting smooth muscle cells to macrophage-like cells with KLF4 in atherosclerotic plaques. Nat Med. 2015;21(6):549–51.PubMedCrossRef
49.
50.
51.
Dahlin JS, et al. Lineage- CD34hi CD117int/hi FcepsilonRI+ cells in human blood constitute a rare population of mast cell progenitors. Blood. 2016;127(4):383–91.PubMedPubMedCentralCrossRef
52.
Shan Y, et al. Increased frequency of peripheral blood follicular helper T cells and elevated serum IL21 levels in patients with knee osteoarthritis. Mol Med Rep. 2017;15(3):1095–102.PubMedPubMedCentralCrossRef
53.
Morita R, et al. Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity. 2011;34(1):108–21.PubMedPubMedCentralCrossRef
54.
Victora GD, et al. Germinal center dynamics revealed by multiphoton microscopy with a photoactivatable fluorescent reporter. Cell. 2010;143(4):592–605.PubMedPubMedCentralCrossRef
55.
Duhen T, et al. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol. 2009;10(8):857–63.PubMedCrossRef
56.
57.
58.
Dardalhon V, et al. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(−) effector T cells. Nat Immunol. 2008;9(12):1347–55.PubMedPubMedCentralCrossRef
59.
60.
61.
Genestier L, et al. TLR agonists selectively promote terminal plasma cell differentiation of B cell subsets specialized in thymus-independent responses. J Immunol. 2007;178(12):7779–86.PubMedCrossRef
62.
Thiriot A, et al. The Bw cells, a novel B cell population conserved in the whole genus Mus. J Immunol. 2007;179(10):6568–78.PubMedCrossRef
63.
Haas KM, et al. B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae. Immunity. 2005;23(1):7–18.PubMedCrossRef
64.
Nussenzweig MC, et al. Dendritic cells are accessory cells for the development of anti-trinitrophenyl cytotoxic T lymphocytes. J Exp Med. 1980;152(4):1070–84.PubMedCrossRef
65.
Wakim LM, et al. Dendritic cell-induced memory T cell activation in nonlymphoid tissues. Science. 2008;319(5860):198–202.PubMedCrossRef
66.
67.
68.
Macal, M., et al., Self-renewal and toll-like receptor signaling sustain exhausted plasmacytoid dendritic cells during chronic viral infection. Immunity, 2018. 48(4): p. 730–744 e5.
69.
Bedoui S, et al. Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nat Immunol. 2009;10(5):488–95.PubMedCrossRef
70.
Hildner K, et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science. 2008;322(5904):1097–100.PubMedPubMedCentralCrossRef
71.
Merad M, et al. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol. 2013;31:563–604.PubMedCrossRef
72.
Yona S, Jung S. Monocytes: subsets, origins, fates and functions. Curr Opin Hematol. 2010;17(1):53–9.PubMedCrossRef
73.
74.
Mukherjee R, et al. Non-classical monocytes display inflammatory features: validation in sepsis and systemic lupus erythematous. Sci Rep. 2015;5:13886.PubMedPubMedCentralCrossRef
75.
Boyette, L.B., et al., Phenotype, function, and differentiation potential of human monocyte subsets. PLoS One, 2017. 12(4): p. e0176460.
76.
Robbins SH, et al. Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling. Genome Biol. 2008;9(1):R17.PubMedPubMedCentralCrossRef
77.
Barbet, G., et al., Sensing microbial viability through bacterial RNA augments T follicular helper cell and antibody responses. Immunity, 2018. 48(3): p. 584–598 e5.
78.
79.
80.
81.
Yang L, Zhang Y. Tumor-associated macrophages. potential targets for cancer treatment Biomark Res. 2017;5:25.
82.
83.
Anderson CF, Mosser DM. A novel phenotype for an activated macrophage: the type 2 activated macrophage. J Leukoc Biol. 2002;72(1):101–6.PubMed
84.
Lu J, et al. Discrete functions of M2a and M2c macrophage subsets determine their relative efficacy in treating chronic kidney disease. Kidney Int. 2013;84(4):745–55.PubMedCrossRef
85.
Butcher MJ, Galkina EV. Phenotypic and functional heterogeneity of macrophages and dendritic cell subsets in the healthy and atherosclerosis-prone aorta. Front Physiol. 2012;3:44.PubMedPubMedCentralCrossRef
86.
87.
Kadl A, et al. Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2. Circ Res. 2010;107(6):737–46.PubMedPubMedCentralCrossRef
88.
89.
Pourcet B, Staels B. Alternative macrophages in atherosclerosis: not always protective! J Clin Invest. 2018;128(3):910–2.PubMedCrossRef
90.
Li X, et al. Mitochondrial reactive oxygen species mediate lysophosphatidylcholine-induced endothelial cell activation. Arterioscler Thromb Vasc Biol. 2016;36(6):1090–100.PubMedPubMedCentralCrossRef
91.
Rombouts, M., et al., Linking CD11b (+) dendritic cells and natural killer T cells to plaque inflammation in atherosclerosis. Mediat Inflamm, 2016. 2016: p. 6467375.
92.
Martinez-Rodriguez JE, et al. Expansion of the NKG2C+ natural killer-cell subset is associated with high-risk carotid atherosclerotic plaques in seropositive patients for human cytomegalovirus. Arterioscler Thromb Vasc Biol. 2013;33(11):2653–9.PubMedCrossRef
93.
Winchester R, et al. Association of elevations of specific T cell and monocyte subpopulations in rheumatoid arthritis with subclinical coronary artery atherosclerosis. Arthritis Rheumatol. 2016;68(1):92–102.PubMedPubMedCentralCrossRef
94.
Mrakovcic-Sutic I, et al. Cross-talk between NKT and regulatory T cells (Tregs) in modulation of immune response in patients with colorectal cancer following different pain management techniques. Coll Antropol. 2011;35(Suppl 2):57–60.PubMed
95.
Dragu R, et al. Predictive value of white blood cell subtypes for long-term outcome following myocardial infarction. Atherosclerosis. 2008;196(1):405–12.PubMedCrossRef
96.
Li S, et al. Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease. Atherosclerosis. 2014;234(2):441–5.PubMedCrossRef
97.
Lievens D, et al. Abrogated transforming growth factor beta receptor II (TGFbetaRII) signalling in dendritic cells promotes immune reactivity of T cells resulting in enhanced atherosclerosis. Eur Heart J. 2013;34(48):3717–27.PubMedCrossRef
98.
99.
100.
Tapp LD, et al. TLR4 expression on monocyte subsets in myocardial infarction. J Intern Med. 2013;273(3):294–305.PubMedCrossRef
101.
Dworacka M, et al. Circulating CD3+56+ cell subset in pre-diabetes. Exp Clin Endocrinol Diabetes. 2014;122(2):65–70.PubMedCrossRef
102.
Cochain C, et al. CD8+ T cells regulate monopoiesis and circulating Ly6C-high monocyte levels in atherosclerosis in mice. Circ Res. 2015;117(3):244–53.PubMedCrossRef
103.
Buono C, et al. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc Natl Acad Sci U S A. 2005;102(5):1596–601.PubMedPubMedCentralCrossRef
104.
Taleb S, Tedgui A, Mallat Z. IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles. Arterioscler Thromb Vasc Biol. 2015;35(2):258–64.PubMedCrossRef
105.
106.
Pastrana JL, et al. Regulatory T cells and atherosclerosis. J Clin Exp Cardiolog. 2012;2012(Suppl 12):2.PubMed
107.
Satoh S, et al. Relationships between inflammatory mediators and coronary plaque composition in patients with stable angina investigated by ultrasound radiofrequency data analysis. Cardiovasc Interv Ther. 2011;26(3):193–201.PubMedCrossRef
108.
109.
Mohanta SK, et al. Artery tertiary lymphoid organs contribute to innate and adaptive immune responses in advanced mouse atherosclerosis. Circ Res. 2014;114(11):1772–87.PubMedCrossRef
110.
Jonasson L, Backteman K, Ernerudh J. Loss of natural killer cell activity in patients with coronary artery disease. Atherosclerosis. 2005;183(2):316–21.PubMedCrossRef
111.
112.
Jaipersad AS, et al. Expression of monocyte subsets and angiogenic markers in relation to carotid plaque neovascularization in patients with pre-existing coronary artery disease and carotid stenosis. Ann Med. 2014;46(7):530–8.PubMedCrossRef
113.
Czepluch FS, et al. Increased proatherogenic monocyte-platelet cross-talk in monocyte subpopulations of patients with stable coronary artery disease. J Intern Med. 2014;275(2):144–54.PubMedCrossRef
114.
Poitou C, et al. CD14dimCD16+ and CD14+CD16+ monocytes in obesity and during weight loss: relationships with fat mass and subclinical atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31(10):2322–30.PubMedCrossRef
115.
Imanishi T, et al. Association of monocyte subset counts with coronary fibrous cap thickness in patients with unstable angina pectoris. Atherosclerosis. 2010;212(2):628–35.PubMedCrossRef
116.
Lee JW, et al. Proinflammatory CD14(+)CD16(+) monocytes are associated with vascular stiffness in predialysis patients with chronic kidney disease. Kidney Res Clin Pract. 2013;32(4):147–52.PubMedPubMedCentralCrossRef
117.
Rothe G, et al. A more mature phenotype of blood mononuclear phagocytes is induced by fluvastatin treatment in hypercholesterolemic patients with coronary heart disease. Atherosclerosis. 1999;144(1):251–61.PubMedCrossRef
118.
Li, T., et al., Huanglian jiedu decoction regulated and controlled differentiation of monocytes, macrophages, and foam cells: an experimental study. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2014. 34(9): p. 1096–1102.
119.
Medina I, et al. Hck/Fgr kinase deficiency reduces plaque growth and stability by blunting monocyte recruitment and intraplaque motility. Circulation. 2015;132(6):490–501.PubMedPubMedCentralCrossRef
120.
Zhang, D., et al., Severe hyperhomocysteinemia promotes bone marrow-derived and resident inflammatory monocyte differentiation and atherosclerosis in LDLr/CBS-deficient mice. Circ Res, 2012. 111(1): p. 37–49.
121.
Donners MM, et al. Hematopoietic miR155 deficiency enhances atherosclerosis and decreases plaque stability in hyperlipidemic mice. PLoS One. 2012;7(4):e35877.PubMedPubMedCentralCrossRef
122.
Fang P, et al. Hyperhomocysteinemia potentiates hyperglycemia-induced inflammatory monocyte differentiation and atherosclerosis. Diabetes. 2014;63(12):4275–90.PubMedPubMedCentralCrossRef
123.
Stoger JL, et al. Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis. 2012;225(2):461–8.PubMedCrossRef
124.
Hu Y, et al. Class A scavenger receptor attenuates myocardial infarction-induced cardiomyocyte necrosis through suppressing M1 macrophage subset polarization. Basic Res Cardiol. 2011;106(6):1311–28.PubMedCrossRef
125.
Alipour A, et al. Leukocyte activation by triglyceride-rich lipoproteins. Arterioscler Thromb Vasc Biol. 2008;28(4):792–7.PubMedCrossRef
126.
Soehnlein O, Lindbom L, Weber C. Mechanisms underlying neutrophil-mediated monocyte recruitment. Blood. 2009;114(21):4613–23.PubMedCrossRef
127.
Gombart AF, et al. Aberrant expression of neutrophil and macrophage-related genes in a murine model for human neutrophil-specific granule deficiency. J Leukoc Biol. 2005;78(5):1153–65.PubMedCrossRef
128.
Ionita MG, et al. High neutrophil numbers in human carotid atherosclerotic plaques are associated with characteristics of rupture-prone lesions. Arterioscler Thromb Vasc Biol. 2010;30(9):1842–8.PubMedCrossRef
129.
Tanaka M, et al. Eosinophil count is positively correlated with coronary artery calcification. Hypertens Res. 2012;35(3):325–8.PubMedCrossRef
130.
Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol. 2005;6(12):1191–7.PubMedCrossRef
131.
Soylu K, et al. The effect of blood cell count on coronary flow in patients with coronary slow flow phenomenon. Pak J Med Sci. 2014;30(5):936–41.PubMedPubMedCentral
132.
Bot I, Shi GP, Kovanen PT. Mast cells as effectors in atherosclerosis. Arterioscler Thromb Vasc Biol. 2015;35(2):265–71.PubMedCrossRef
133.
Wu, C., et al., Characterization of IL-12 receptor beta1 chain (IL-12Rbeta1)-deficient mice: IL-12Rbeta1 is an essential component of the functional mouse IL-12 receptor. J Immunol, 1997. 159(4): p. 1658–65.
134.
Letimier FA, et al. Chromatin remodeling by the SWI/SNF-like BAF complex and STAT4 activation synergistically induce IL-12Rbeta2 expression during human Th1 cell differentiation. EMBO J. 2007;26(5):1292–302.PubMedPubMedCentralCrossRef
135.
Afkarian M, et al. T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4+ T cells. Nat Immunol. 2002;3(6):549–57.PubMedCrossRef
136.
Athie-Morales V, et al. Sustained IL-12 signaling is required for Th1 development. J Immunol. 2004;172(1):61–9.PubMedCrossRef
137.
138.
Kelly-Welch AE, et al. Interleukin-4 and interleukin-13 signaling connections maps. Science. 2003;300(5625):1527–8.PubMedCrossRef
139.
Bettelli E, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441(7090):235–8.PubMedCrossRef
140.
141.
Ichiyama K, et al. Foxp3 inhibits RORgammat-mediated IL-17A mRNA transcription through direct interaction with RORgammat. J Biol Chem. 2008;283(25):17003–8.PubMedCrossRef
142.
143.
Tone Y, et al. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol. 2008;9(2):194–202.PubMedCrossRef
144.
Webster KE, et al. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med. 2009;206(4):751–60.PubMedPubMedCentralCrossRef
145.
Niiro H, Clark EA. Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol. 2002;2(12):945–56.PubMedCrossRef
146.
Kurosaki T. Genetic analysis of B cell antigen receptor signaling. Annu Rev Immunol. 1999;17:555–92.PubMedCrossRef
147.
Garraud O, et al. Revisiting the B-cell compartment in mouse and humans: more than one B-cell subset exists in the marginal zone and beyond. BMC Immunol. 2012;13:63.PubMedPubMedCentralCrossRef
148.
Cariappa A, et al. The follicular versus marginal zone B lymphocyte cell fate decision is regulated by Aiolos, Btk, and CD21. Immunity. 2001;14(5):603–15.PubMedCrossRef
149.
Croker BA, et al. The Rac2 guanosine triphosphatase regulates B lymphocyte antigen receptor responses and chemotaxis and is required for establishment of B-1a and marginal zone B lymphocytes. J Immunol. 2002;168(7):3376–86.PubMedCrossRef
150.
Thome M. CARMA1, BCL-10 and MALT1 in lymphocyte development and activation. Nat Rev Immunol. 2004;4(5):348–59.PubMedCrossRef
151.
Rickert RC, Jellusova J, Miletic AV. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev. 2011;244(1):115–33.PubMedPubMedCentralCrossRef
152.
Mildner A, Jung S. Development and function of dendritic cell subsets. Immunity. 2014;40(5):642–56.PubMedCrossRef
153.
154.
155.
Hacker C, et al. Transcriptional profiling identifies Id2 function in dendritic cell development. Nat Immunol. 2003;4(4):380–6.PubMedCrossRef
156.
Tamura T, et al. IFN regulatory factor-4 and -8 govern dendritic cell subset development and their functional diversity. J Immunol. 2005;174(5):2573–81.PubMedCrossRef
157.
Becker AM, et al. IRF-8 extinguishes neutrophil production and promotes dendritic cell lineage commitment in both myeloid and lymphoid mouse progenitors. Blood. 2012;119(9):2003–12.
158.
Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature. 2015;523(7559):231–5.PubMedCrossRef
159.
Spranger, S., et al., Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell, 2017. 31(5): p. 711–723 e4.
160.
Wu L, et al. RelB is essential for the development of myeloid-related CD8alpha- dendritic cells but not of lymphoid-related CD8alpha+ dendritic cells. Immunity. 1998;9(6):839–47.PubMedCrossRef
161.
Lewis KL, et al. Notch2 receptor signaling controls functional differentiation of dendritic cells in the spleen and intestine. Immunity. 2011;35(5):780–91.PubMedPubMedCentralCrossRef
162.
Caton ML, Smith-Raska MR, Reizis B. Notch-RBP-J signaling controls the homeostasis of CD8- dendritic cells in the spleen. J Exp Med. 2007;204(7):1653–64.PubMedPubMedCentralCrossRef
163.
Ichikawa E, et al. Defective development of splenic and epidermal CD4+ dendritic cells in mice deficient for IFN regulatory factor-2. Proc Natl Acad Sci U S A. 2004;101(11):3909–14.PubMedPubMedCentralCrossRef
164.
Suzuki, S., et al., Critical roles of interferon regulatory factor 4 in CD11bhighCD8alpha- dendritic cell development. Proc Natl Acad Sci U S A, 2004. 101(24): p. 8981–6.
165.
Vander Lugt B, et al. Transcriptional programming of dendritic cells for enhanced MHC class II antigen presentation. Nat Immunol. 2014;15(2):161–7.PubMedCrossRef
166.
Bajana S, et al. IRF4 promotes cutaneous dendritic cell migration to lymph nodes during homeostasis and inflammation. J Immunol. 2012;189(7):3368–77.PubMedPubMedCentralCrossRef
167.
Naik SH, et al. Cutting edge: generation of splenic CD8+ and CD8- dendritic cell equivalents in Fms-like tyrosine kinase 3 ligand bone marrow cultures. J Immunol. 2005;174(11):6592–7.PubMedCrossRef
168.
Laouar Y, et al. STAT3 is required for Flt3L-dependent dendritic cell differentiation. Immunity. 2003;19(6):903–12.PubMedCrossRef
169.
Ghosh HS, et al. Continuous expression of the transcription factor e2-2 maintains the cell fate of mature plasmacytoid dendritic cells. Immunity. 2010;33(6):905–16.PubMedPubMedCentralCrossRef
170.
Serbina NV, et al. Sequential MyD88-independent and -dependent activation of innate immune responses to intracellular bacterial infection. Immunity. 2003;19(6):891–901.PubMedCrossRef
171.
De Trez C, et al. iNOS-producing inflammatory dendritic cells constitute the major infected cell type during the chronic Leishmania major infection phase of C57BL/6 resistant mice. PLoS Pathog. 2009;5(6):e1000494.PubMedPubMedCentralCrossRef
172.
Seo SU, et al. Type I interferon signaling regulates Ly6C(hi) monocytes and neutrophils during acute viral pneumonia in mice. PLoS Pathog. 2011;7(2):e1001304.PubMedPubMedCentralCrossRef
173.
Iwasaki H, Akashi K. Myeloid lineage commitment from the hematopoietic stem cell. Immunity. 2007;26(6):726–40.PubMedCrossRef
174.
Zhu YP, Thomas GD, Hedrick CC. 2014 Jeffrey M. Hoeg award lecture: transcriptional control of monocyte development. Arterioscler Thromb Vasc Biol. 2016;36(9):1722–33.PubMedPubMedCentralCrossRef
175.
176.
177.
178.
Hanna RN, et al. The transcription factor NR4A1 (Nur77) controls bone marrow differentiation and the survival of Ly6C- monocytes. Nat Immunol. 2011;12(8):778–85.PubMedPubMedCentralCrossRef
179.
Qin H, et al. LPS induces CD40 gene expression through the activation of NF-kappaB and STAT-1alpha in macrophages and microglia. Blood. 2005;106(9):3114–22.PubMedPubMedCentralCrossRef
180.
Wang N, Liang H, Zen K. Molecular mechanisms that influence the macrophage m1-m2 polarization balance. Front Immunol. 2014;5:614.PubMedPubMedCentral
181.
Krausgruber T, et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol. 2011;12(3):231–8.PubMedCrossRef
182.
183.
Tschopp J, Martinon F, Burns K. NALPs: a novel protein family involved in inflammation. Nat Rev Mol Cell Biol. 2003;4(2):95–104.PubMedCrossRef
184.
Imtiyaz HZ, Simon MC. Hypoxia-inducible factors as essential regulators of inflammation. Curr Top Microbiol Immunol. 2010;345:105–20.PubMedPubMedCentral
185.
186.
Rius J, et al. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature. 2008;453(7196):807–11.PubMedPubMedCentralCrossRef
187.
188.
O'Farrell AM, et al. IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and -independent pathways. EMBO J. 1998;17(4):1006–18.PubMedPubMedCentralCrossRef
189.
Bouhlel MA, et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 2007;6(2):137–43.PubMedCrossRef
190.
191.
Sharma N, et al. Myeloid Kruppel-like factor 4 deficiency augments atherogenesis in ApoE-/- mice—brief report. Arterioscler Thromb Vasc Biol. 2012;32(12):2836–8.PubMedPubMedCentralCrossRef
192.
Babaev VR, et al. Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2005;25(8):1647–53.PubMedCrossRef
193.
194.
Zhang W, Xu W, Xiong S. Macrophage differentiation and polarization via phosphatidylinositol 3-kinase/Akt-ERK signaling pathway conferred by serum amyloid P component. J Immunol. 2011;187(4):1764–77.PubMedCrossRef
195.
Zhang W, Xu W, Xiong S. Blockade of Notch1 signaling alleviates murine lupus via blunting macrophage activation and M2b polarization. J Immunol. 2010;184(11):6465–78.PubMedCrossRef
196.
197.
Moore KW, et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683–765.PubMedCrossRef
198.
Murray PJ. Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response. Curr Opin Pharmacol. 2006;6(4):379–86.PubMedCrossRef
199.
Boyle JJ, et al. Activating transcription factor 1 directs Mhem atheroprotective macrophages through coordinated iron handling and foam cell protection. Circ Res. 2012;110(1):20–33.PubMedCrossRef
200.
Hayashi C, et al. Protective role for TLR4 signaling in atherosclerosis progression as revealed by infection with a common oral pathogen. J Immunol. 2012;189(7):3681–8.PubMedPubMedCentralCrossRef
201.
Clement M, et al. Control of the T follicular helper-germinal center B-cell axis by CD8(+) regulatory T cells limits atherosclerosis and tertiary lymphoid organ development. Circulation. 2015;131(6):560–70.PubMedCrossRef
202.
203.
Oriss, T.B., et al., Crossregulation between T helper cell (Th)1 and Th2: inhibition of Th2 proliferation by IFN-gamma involves interference with IL-1. J Immunol, 1997. 158(8): p. 3666–72.
204.
Laurence, A., et al., Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity, 2007. 26(3): p. 371–81.
205.
206.
207.
Wilson GL, et al. cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions. J Exp Med. 1991;173(1):137–46.PubMedCrossRef
208.
Pao LI, et al. B cell-specific deletion of protein-tyrosine phosphatase Shp1 promotes B-1a cell development and causes systemic autoimmunity. Immunity. 2007;27(1):35–48.PubMedCrossRef
209.
Nguyen KD, et al. Circadian gene Bmal1 regulates diurnal oscillations of Ly6C(hi) inflammatory monocytes. Science. 2013;341(6153):1483–8.PubMedCrossRef
210.
Davison AM, King NJ. Accelerated dendritic cell differentiation from migrating Ly6C(lo) bone marrow monocytes in early dermal West Nile virus infection. J Immunol. 2011;186(4):2382–96.PubMedCrossRef
211.
Rackov, G., et al., p21 mediates macrophage reprogramming through regulation of p50-p50 NF-kappaB and IFN-beta. J Clin Invest, 2016. 126(8): p. 3089–3103.
212.
Myers MP, et al. TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J Biol Chem. 2001;276(51):47771–4.PubMedCrossRef
213.
Dickensheets H, et al. Suppressor of cytokine signaling-1 is an IL-4-inducible gene in macrophages and feedback inhibits IL-4 signaling. Genes Immun. 2007;8(1):21–7.PubMedCrossRef
214.
215.
Menezes S, et al. The heterogeneity of Ly6C(hi) monocytes controls their differentiation into iNOS(+) macrophages or monocyte-derived dendritic cells. Immunity. 2016;45(6):1205–18.PubMedPubMedCentralCrossRef
216.
217.
218.
219.
220.
221.
Foks AC, et al. CD11b+Gr-1+ myeloid-derived suppressor cells reduce atherosclerotic lesion development in LDLr deficient mice. Cardiovasc Res. 2016;111(3):252–61.PubMedCrossRef
222.
Ostrand-Rosenberg S. Myeloid derived-suppressor cells: their role in cancer and obesity. Curr Opin Immunol. 2018;51:68–75.PubMedCrossRef
223.
224.
225.
226.
Trikha M, et al. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res. 2003;9(13):4653–65.PubMedPubMedCentral
227.
Guo Y, et al. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 2012;38(7):904–10.PubMedCrossRef
228.
Metadata
Title
Immune cell subset differentiation and tissue inflammation
Authors
Pu Fang
Xinyuan Li
Jin Dai
Lauren Cole
Javier Andres Camacho
Yuling Zhang
Yong Ji
Jingfeng Wang
Xiao-Feng Yang
Hong Wang
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2018
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-018-0637-x

Other articles of this Issue 1/2018

Journal of Hematology & Oncology 1/2018 Go to the issue

Review

Exosomal miRNAs in hepatocellular carcinoma development and clinical responses

Research

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

Review

Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions

Review

Next generation of immune checkpoint therapy in cancer: new developments and challenges

Research

A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase

Review

Role of platelets and platelet receptors in cancer metastasis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits